Professional Documents
Culture Documents
1
Principles of Endocrinology & Metabolism
Homeostasis is the key principle of endocrine physiology
Endocrine glands are key nodal points in hormonal signaling pathways
NEWS ALERT: There’s an obesity epidemic in the USA! Metabolic syndrome, diabetes, hypercholesterolemia, too
Diagnosis
History: mostly pattern recognition (not too much pathognomonic stuff)
Exam: test hypotheses; discovery:
o asymptomatic thyroid nodule: 5% are cancers
st
o absent Achilles tendon reflex can be 1 sign of diabetic peripheral neuropathy
Lab testing is big: (need context – fed/fasted, time of day, etc).
Imaging: use selectively! Make a biochemical Dx first.
Pathology: check tumor prognosis
Disease Mechanisms
Gland hypoplasia (developmental defect)
Congenital /
Hormone biosynthetic defect (abnormal hormone or enzyme gene)
hereditary
Hormone resistance (abnormal hormone receptor / signaling protein gene)
Tissue hypersensitivity
2
Primary vs Secondary Hormone Deficiency
Primary deficiency: end gland is defective
Secondary deficiency: defect in upstream gland in pathway
Also applies to hyperfunction!
If hypothalamus messed up: call it “3°”or can call it “2°” if not sure where problem is (hypothalamus vs pituitary)
“Secondary” “Primary”
Hypothalamic
Pituitary Hormone “End-hormone”
Releasing Hormone
CRH ACTH Cortisol
TRH TSH Thyroxine
GNRH LH/FSH Testosterone/Estradiol
GHRH GH IGF-1
3
Diabetes Mellitus
Introduction / Diagnosis of Diabetes
Diabetes: need ONE of...
Fasting plasma glucose ≥ 126 mg/dL
Casual plasma glucose ≥ 200 mg/dL AND symptoms of diabetes
Oral glucose tolerance test ≥ 200 mg/dL (2 hrs post 75g oral glc load)
HbA1c ≥ 6.5%
Note that there are 3 types of prevention – most physicians end up working in 2° / 3° prevention
Preventing complications is key to management
Symptom Pathophysiology
1. Polydypsia Hyperosmolarity (glucose adds 5.5 mOsm/L per 100 mg/dL) + dehydration thirst
Polydypsia ↑ fluid intake large urine volumes
2. Polyuria
Glucose-induced osmotic diuresis
3. Weight loss Calories lost as glucosuria negative caloric balance, wt loss
4. Polyphagia Inefficient utilization of ingested calories & glucosuria. Insulin ↑ appetite?
5. Blurred vision Lens stiffens (sugars – not retinopathy early!)
Others: poor wound healing, vaginitis, gingivitis, dental caries (↓ vascular flow, ↑ sugars – good for infections, etc.)
4
Endstage acute complications (FATAL IF NOT TREATED)
DIABETIC KETOACIDOSIS
metabolic acidosis; fatal if untreated
Virtually complete lack of insulin unrestrained lipolysis hepatic conversion to ketone bodies
Pathogenesis
ketone bodies accumulate as organic acids acidosis
Kussmaul respirations Metabolic acidosis
Diagnosis
Hyperglycemia + ketones in blood / urine
Insulin
Treatment Electrolytes
Fluids
Management:
Pay special attention to known risk factors: BP, chol, smoking, blood glucose / A1c
Preventative measures (aspirin, exercise)
Preventative foot care
5
Microvascular Disease: diabetic retinopathy
#1 cause blindness in adults 20-74 yo
Related to duration of diabetes & glycemic control
↑ risk with hyperglycemia, presence of nephropathy, ↑ BP
o Pregnancy may transiently exacerbate retinopathy in type 1 DM pts
Vitreous hemorrhage:
If untreated, can bleed into vitreous lose vision suddenly!
Pathogenesis: theories
Vasoproliferative factors (IFG, VEGF)
Ischemic / intraocular pressure changes
Basement membrane, mural cell leak
Management:
Prevent (good glucose control)
Early detection (eye screening)
Laser photocoagulation (if macular edema / proliferative retinopathy detected)
Vitrectomy (to replace late-stage, scarred vitreous
Experimental: vasoproliferation inhibitiors (anti-VEGF) into vitreous
6
Management:
Pictures: neuopathies
Management:
Difficult combo: Immobilization, abx, revascularization, time
Goal: prevent / minimize amputations (gangrene / infection)
7
“Diabetic Control” & long-term diabetic complications
Diabetic control: keep blood glucose levels as close to normal as possible
Self-monitoring of blood glucose (prick finger), or
HbA1c (glycated hemoglobin): indicator of glycemic control over 2-3 months (life span of RBC ≈ 120d)
Epidemiology: far less common than type 2 (5-10% all diabetes), ↑ in N. Europe, ↓ in Asia
Pathophysiology of Type 1 DM
An autoimmune disease:
Circulating autoantibodies in ≈ 80% at dx; precede onset by 3-4 yrs
o Anti-islet-cell
o Anti-GAD (glutamic acid decarboxylase)
o Anti-insulin
Lymphocytic infiltration of pancreas on path (“insulitis”)
Associated with other autoimmune dz
o Vitiligo o Addison’s disease
o UC o Rheumatoid arthritis
o Hypothyroidism
Associated with certain MHC alleles (↑ or ↓ risk)
Clinical characteristics
Onset usually < 35 yo
Frequently negative FHx
Thin / normal body wt
Ketoacidosis is more common end-stage acute complication
(complete insulin deficiency)
Labile metabolic state (blood glucose bounces up and down – little or no endogenous insulin – see pic)
8
Treatment:
Type 1 always requires insulin therapy (multiple doses daily)
Metabolic lability harder to treat
New directions: window of opportunity for prevention (prior to β-cell destruction)? Better insulin delivery?
Epidemiology: most common form by far (90% cases), prevalence in population proportional to (abdominal) obesity
Disease of prosperity: too many nutrients!
↑ in AA, Hispanics, Native Americans vs Caucasians
Pathophysiology
No evidence for autoimmunity
o no HLA associations, anti-islet Ab, link with autoimmune dz
o Not inflammatory (see AMYLOID DEPOSITS in islets)
9
Clinical Characteristics
Onset usually > 35 yo (not always: current epidemic of childhood type 2 DM in overweight youth)
FHx usually positive! (stronger heritability than type 1 DM)
Usually (80%) associated with obesity
Endogenous insulin reserve present; often have HYPERINSULINEMIA
Can treat with diet / exercise alone or ± oral insulin agents ± exogenous insulin
Relatively stable metabolic state (not prone to wide swings)
Genetics
Active field – esp. with genome-wide screens (≈ 10 genes associated, strongest is TCF7L2 but still only ↑ risk 50%)
Other associations will be found: probably polygenic + environmental
Type 1 vs Type 2 Diabetes Mellitus
Type 1 Type 2
Formerly known as IDDM, Juvenile Onset NIDDM, Adult Onset
Without Insulin Rx Ketoacidosis, death Usually, no ketosis
Age of Onset Usually <35 Usually >35
Obesity Unusual Common
Family History Usually Negative Usually Positive
HLA Association Yes No
Endogenous Insulin Usually Absent Usually Present
Insulin Resistance Usually Absent Usually Present
Metabolic Course Labile Usually Stable
Response to Pills No Yes
Etiology Autoimmune Non-Autoimmune
Gestational diabetes
Diabetes first diagnosed during pregnancy
↓ insulin, ↑ glucagon
Glycogenolysis, hepatic gluconeogenesis (support blood
4-24 hrs after eating
Post-absorptive glucose without dietary CHO around)
(“overnight fast”)
Lipolysis activated (freeing FA from adipose tissue)
Fatty acids become main source for glucose fuel
11
Normal Blood Glucose Homeostasis
Counter-regulatory hormones
(act in opposition to insulin: “insulin against the world!”)
o Glucagon, epinephrine, corticosteroids, growth hormone, norepi
o Protect glucose if it falls too low
Counter-regulatory hormones produce the “fight or flight response” – in response to stress, crisis, hypoglycemia
↑ blood glucose (glucose = fuel for exercise) Rapid heart beat (ready to run or fight)
↑ anxiety (mental alertness, apprehension) Sweating (dissipate excess heat)
Vasodilate periphery (optimal muscle oxygenation)
Hypoglycemia
Disturbing but not as dangerous (mild/moderate hypoglycemia) VERY DANGEROUS – SEVERE HYPOGLYCEMIA – TREAT‼
12
Fasting hypoglycemia: partial DDx
Insulinoma:
Diagnosis:
o Symptomatic fasting hypoglycemia (abnormal to develop Sx, even during prolonged fast!)
o Inappropriate hyperinsuilinism (may be subtle), or
o 72h diagnostic fast (look for symptomatic hypoglycemia / inappropriate hyperinsuilinism)
Plasma glucose falls, but insulin doesn’t – insulin should drop like a rock to preserve PG, but doesn’t!
Management: image to localize, surgery to remove (80% are benign & surgically cured!)
Post-oral glucose
Alimentary hypoglycemia (rapid gastric emptying, after gastric bypass surgery, for instance?)
o Maybe excess GLP-1 stimulation from rapid gastric emptying?
13
Dietary Management of Diabetes & Hyperlipidemia
Goals of diabetes management
Targets
1. Try to get blood glucose in normal range (as close as possible)
Pre-prandial 80-120 mg/dL
Glycemic
2. Lipid / lipoprotein profile that ↓ risk macrovascular disease
o DM is a cardiovascular risk equivalent (= previous MI) Post-prandial (2h) < 180 mg/dL
3. Blood pressure that reduces risk of vascular disease Bedtime 100-140 mg/dL
HbA1c 7%
Other goals LDL Cholesterol < 100 (<70?) mg/dL
Prevent/treat chronic complications Blood Pressure < 130 / 80
o (obesity, dyslipidemia, CVD, HTN, nephropathy)
Encourage healthy food choices (keep pleasure of eating – only limit if good scientific evidence)
Address individual / cultural needs
Carbohydrates
Sugars (↑ blood sugar acutely)
Starches (later & longer-lasting)
Fiber (don’t raise sugars like other complex CHOs – really good!)
Recommendations:
CHO and monounsaturated fat should be 60-70% of energy intake
Get it from whole grains (dietary fiber), fruits, vegetables, low-fat milk
Total amount more important than source / type for diabetics
Use other CHO sources instead of sucrose-containing foods (to help loose weight)
Non-nutritive sweeteners: don’t cause cancer
Proteins
Should be 15-20% daily energy (no restriction if normal renal function)
Does not increase plasma glucose in type 2 DM but can ↑ serum insulin response
Protein requirements may be greater than RDA in pts with uncontrolled diabetes
o From ↑ protein turnover; worry about protein malnutrition in developing world
14
Fats
Linoleic acid, α-linoleic acid Vegetable / plant oils
Polyunsaturated fatty acids (Ω-3) Eicosapentoic acid (EPA)
Fish, plankton
Docosohexanoic acid (DHA)
Oleic acid (cis-form)* Plant/nut oils, nuts
Monounsaturated fatty acids
Elaidic acid (trans-form)* Margarine, hydrogenated oils
Lauric acid, myristic acids, palmitic Red meat, poultry, dairy products,
Saturated fatty acids
acids, stearic acids processed grains
* cis forms are “healthy” form of monounsaturated fats – trans-fats ↑ CVD risk
Saturated fat just does pretty much everything bad Polyunsaturated fats help lower LDL a little
Monounsaturated fats (here cis) help lower LDLs Fish oils (omega-3) lowers TGs
Trans-unsaturated fats raise LDLs Plant sterols help lower LDL / total cholesterol
Recommendations
<7% of energy intake from saturated fat (↓LDL-cholesterol)
Dietary cholesterol intake <200 mg/day (↓ LDL-cholesterol)
Minimize intake of transunsaturated fatty acids
Polyunsaturated fat: 2 or more servings of fish per week recommended
Recommendations:
↓ energy intake Lifestyle changes
education (food labels)
drop 500-1000 calories vs maintenance reduce fat (< 40% daily energy)
shoot for 5-7% weight loss to start (manageable) regular physical activity
Pedometer with goal (e.g. 10k steps/day) can be useful
Exercise and behavior modification are adjuncts
Dyslipidemia
Goal: Lower LDL-chol (prevent CVD)
Limit saturated fat & transunsaturated fatty acids to < 7% energy intake
o If weight loss not desired, replace with CHO or monounsaturated fat
↑ plant stanols / sterols, soluble fiber
Calculating Carbohydrates
1 ADA CHO exchange = 1 serving = one starch / bread = 15 g CHO
16
Thyroid Pathophysiology
Basic Anatomy
Thyroid is at the base of neck in the center,
Below the thyroid cartilage, has nothing
to do with thyroid gland
Pyramidal lobe – embryological
remnant of the thryoglossal duct
Easily palpable (very close to skin), can
impinge on other structures
Embryology review
Thyroid descends can get thyroglossal duct cysts or other remnants of thyroid Lingual thyroid (ectopic thyroid
down front of neck, duct anywhere along the pathway (pics) gland) – mass in back of mouth
ends up at base (posterior midline); can be only
thyroid in body! Careful in removal!
Higher brain centers (e.g. cold exposure) can trigger TRH release
E.g. when baby born: TRH TSH surge when leaving warm womb
17
The Thyroid
Organized into spherical follicles
Lined by thyrocytes
Contain colloid
(which contains thyroglobulin, storage form of thyroid hormone)
18
What happens when TBG levels change?
TBG sucks up free T4 (↓ at first); but then pituitary senses ↓ TBG excess more free T4 downregulate TSH, T4
free T4 and secretes more TSH ↑ T4, sucked up by TBG
End result: SAME FREE T4, MORE TOTAL T4 End result: SAME FREE T4, LESS TOTAL T4
Remember free T4 is what can enter cells – free T4 sensed, free T4 ( T3) has biological effect
T4 T3 in peripheral tissues
E.g. liver, muscle 1,5’ deiodinase removes one of the iodines
o “Selenoproteins” – enzyme has selenium atom inside
Dynamic balance
100% T4 made in thyroid
About 80% T3 made in periphery
If you’re hungry, sick, etc. – don’t want to make T3 (would speed up metabolism!)
BMR ↓ with starvation (not a good way to lose weight)
Very low T3 in ICU! “euthyroid sick state”
T3↓ but rT3↑ (deiodinase enzyme levels adjusted)
19
Thyroid hormone receptor family
Nuclear receptor superfamily
Constitutively bound to chromatin
Involved in DNA binding / transcription
o to upregulate / downregulate gene expression
o E.g. ↓ TSH, ↑ hepatic proteins
o Often complexes with retinoic acid receptor (RxR)
** in central hypothyroidism, can have a dysfunctional TSH that is picked up by assay but not active!
If someone’s hypothyroid, they should have a high TSH – normal TSH suggests central hypothyroidism
20
Algorithm for Thyroid Testing
Down the middle: normal! No more testing
Thyrotoxicosis (hyperthyroidism)
Just means you’re hyperthyroid (looking “toxic” - tachy, sweaty, like you have an infection)
State of tissue exposure to ↑ concentrations of thyroid hormone
Common: lifetime 2% prevalence in females
Signs:
Eyelid retraction (Graves’ disease proptosis) ↑ reflexes
Warm, moist (diaphoretic), smooth skin Osteopenia, hypercalcemia, hypercalcuria
Tremor Onycholysis (nails separates from nailbed, get
Goiter dirt under)
Tachycardia, arrhythmias, A-fib, SBP ↑, DBP ↓
Etiology of Hyperthyroidism
Graves’ disease is #1
Can also get toxic nodules (benign lumps in old age), subacute thyroiditis, very rare TSH tumors
21
Graves’ disease:
Typical patient: young woman with goiter, periorbital swelling
Epidemiology:
#1 cause of hyperthyroidism
occurs in 2% women, has genetic influences (but only 40-70% MZ twins)
Sex ratio 5-10:1 Females ≫ Males (hormonal?)
Signs / symptoms:
general hyperthyroid symptoms, can hear bruit over thyroid (pretty specific finding ↑ blood flow through thyroid)
Diffuse goiter
Ophthalmopathy: (present in 90% pts, ± clinically obvious): NO SPECS
o No findings
o Only stare
o Swelling
o Proptosis
o EOM dysfunction (inf. rectus is #1 – can’t look up)
o Corneal involvement
o Sight loss (ischemic optic neuropathy)
Etiology:
Autoimmune disease: thyroid stimulating antibodies (TSAb)
o Against TSH receptor but stimulate growth / function
o Bypassing TSH stimulating thyroid receptors!
Possible triggers: smoking / stress / infection
↑ autoreactive helper T cells (APCs / suppressor cells?)
Diagnosis:
Thyroid Stimulating Abs (can see in hashimoto’s thyroiditis too)
o only see in autoimmune thyroid disease;
o Hashimoto’s- damage is too great ↓ thyroid function
Radioactive iodine check thyroid uptake (should ↑ enhancement)
Toxic nodules
“Hot” thyroid nodules are more common in older people
Graves’ disease is a disease of younger people
“Hot” because they make T3 + T4
↑ T3/4, but ↓ TSH from pituitary, so contralateral
lobe atrophies (common idea in endocrinology)
Some have genetic mutations
22
Toxic Multinodular goiter
Just a more extreme case of the solitary toxic nodules
Goiter just means big thyroid
Labs in hyperthyroidism
↑ free T4 in serum
↑ serum T3
↓ serum TSH
Radioiodine uptake ↑ in most forms of hyperthyroidism
o ↓ in thyroiditis, factitious, struma ovarii
Treatment of Hyperthyroidism
Antithyroid drugs Radioiodine Surgery
High cure rate
Non-ablative > 90% cure rate, 100% hypothyroidism
Serious complications
Side-effects: 5-20% Simple, most cost-effective, few side effects
Expensive
Hypothyroidism
Systemic syndrome characterized by deficiency of thyroid hormone (or, rarely, intrinsic resistance to its effects)
Symptoms of hypothyroidism
Fatigue, lethargy, sleepiness Slight weight gain, ↓
Mental impairment, depression, dementia appetite
Menstrual disturbances (esp menorrhagia) Constipation
Cold intolerance Arthralgias
Dry skin, ↓ perspiration Paresthesias
Signs of hypothyroidism
Goiter ↓ body hair
Slow speech, hoarseness Dyspnea, hypoventilation,
Cool, dry skin sleep apnea
↓, slow reflexes Multifactorial anemia
Bradycardia, pericardial effusion Hypoosmolar state (hypoNa)
23
Dermatologic manifestations
Symptoms: dry, yellowed skin
Signs: myxedema (nonpitting edema due to GAG deposition)
o different than pretibial myxedema in Graves’
o Cool, dry skin with brittle nails too
Growth in kids:
Obesity, ↓ growth, immature body proportions
Resolves with TSH administration
Etiology of hypothyroidism
Developed world:
Hasimoto’s thyroiditis (autoimmune) is #1
Also:
o congenital absence of thyroid / enzyme defect
o postablative (RAI / surgery)
o drugs (lithium, amiodarone / other I-containing drugs)
Hashimoto’s Thyroiditis
(a.k.a. “Autoimmune thyroiditis”, “chronic lymphocytic thyroiditis)
Lab findings
Total serum T4: ↓ (but be careful of binding protein abnormalities)
Free serum T4: ↓
Serum T3: ↓ or nL
TSH: ↑ (unless central)
RadioI uptake: usually low, but overlaps with normal
Treatment of hypothyroidism
Thyroxine (T4), either brand name or generics (preparation of course)
L-T3 (Cytomel): has specific indications
24
Thyroiditis
Subacute thyroiditis
Self-limited, nonsuppurative inflammation of the thyroid
o Infectious disease, often preceded by viral illness
Systemic symptoms: malaise, fever, ↑↑↑ ESR
Big, really painful thyroid(see pic to right)
Mild hyperthyroidism followed by mild hypothyroidism; usually complete recovery
Labs in Thyroiditis
↑ T3/4 ↓ TSH
↓ uptake of radioactive iodine
25
Pituitary Gland
Anatomy Review
Negative feedback systems at work too: true for pretty much all of the axes
Hormone can feed back on hypothalamus, anterior pituitary
Nomenclature of lesions
Microadenoma*: < 1 cm in diameter Secretory: produces hormone in excess
Macroadenoma*: > 1 cm in diameter Nonfunctional: ↓ hormone production
* normal height of pituitary is 9mm so > 1 cm is growing out of sella turcica!
26
Lesions: radiographic appearance
Hypopituitarism
Gonadotrophin deficiency
TSH deficiency ACTH deficiency GH deficiency
Women Men
↑ fat, ↓ lean body mass
Fatigue Weakness ↓ exercise capacity,
Amenorrhea Infertility
Cold intolerance Orthostasis performance
Infertility ↓ libido / impotency
Dry skin Dizziness ↓ muscle strength
↓ 2° sex Small testes (no FSH)
Constipation Pallor ↓ HDL chol,
characteristics ↓ 2° sex characteristics Weight gain Hypoglycemia ↓ bone mineral density
Impaired cardiac fxn
These are secondary deficiencies – nothing wrong with the end organ!
Can get these singly, in combo, or all (panhypopituitarism)
1. Tension-type headache is early sign: tumor grows up, stretches diaphragmatic sella (has nerves in it)
2. Optic chiasm compression is next: inferior posterior portion compromised (SUPERIOR TEMPORAL FIELDS)
a. Can be one or both sides eventually bitemporal hemianopsias
Secretory adenomas
See below for more detail
Secretory Adenomas
Prolactinoma Population: women with % with prolactinoma
#1 for secretory pituitary adenomas Amenorrhea 20%
Galactorrhea 30%
Clinical manifestations: either biochemical or mechanical Infertility 35%
Galactorrhea + oligoamenorrhea 70-75%
Mechanical origin: physical effects (as discussed above):
↓ gonadatroph function, visual field defects, CN palsies, H/A
When prolactin is high, it feeds back to the hypothalamus and shuts off gonadotrophin releasing hormone function
↓ LH, ↓ FSH (2° form of hypogonadism)
28
Galactorrhea: can be present in males or females!
Pathological causes:
o prolactin-secreting tumors (prolactinomas)
o 1/3 of growth-hormone secreting tumors too! (check GH with ↑ prolactin)
o Large sellar masses / hypothalalmic masses
Dopamine is inhibitory: if ↓ dopamine, ↑ prolactin (but coming from normal pituitary)
If normal pituitary is making prolactin, treatment is surgical! (prolactin usually > 200)
If tumor is making prolactin (prolactinoma), treatment is medical!
IF PROLACTIN > 250, it HAS to be a PROLACTINOMA! (small prolactinoma can be < 250)
o Primary hypothyroidism, polycystic ovary, renal failure can ↑ prolactin
o Drugs: dopamine receptor blockers, catecholamine depletors
o Chest wall trauma (suckling reflex from nipple to brain disrupt ↑ prolactin – uncommon)
Diagnosis
Elevated fasting prolactin
R/O pregnancy, hypothyroidism, renal failure
Drug history (no D2 receptor antagonists?)
MRI if everything else ruled out
Acromegaly + gigantism: excess GH while growth plates are still open can get ↑ vertical growth (gigantism)
29
Diagnosis of acromegaly
Growth hormone releasing hormone (GHRH) stimulates GH release
Somatostatin is inhibitory (SRIF)
Most of the effects of GH are due to generation of IGF-1 (insulin-like growth factor 1)
TSH-secreting tumors
Least common
TSH stimulates thyroid to make too much thyroid hormone hyperthyroidism
Like Graves’ w/o eye findings (tremor, SOB, wt loss, weakness, tachycardia, insomnia)
Primary treatment: surgical
Craniopharyngioma
Squamous epithelial tumor arising from stalk (or hypothalamus, or 3rd ventricle)
Has solid & cystic components
Peak incidence in childhood
Significant headaches panhypopituitarism; also diabetes insipidus
Surgical excision if small; destructive when they get large
Recurrence: try surgery again, ± radiation
Pituitary Apoplexy
Spontaneous hemorrhage into pituitary tumor (2-5% of all untreated pituitary tumors)
Severe H/A, N/V, fever, stiff neck – pts usually go right to ED
o “worst headache of my life” – usually misdiagnosed as subarachnoid hemorrhage, meningitis
o Visual loss, diplopia, ptosis too (expansion of blood)
o Meningismus sx from necrotic tissue exploding into CSF
Panhypopituitarism (hemorrhage) acute cortisol deficiency (can be life threatening!)
30
Hypopituitarism: monohormonal failures
Usually inherited (can be acquired)
Kallman syndrome: failure to elaborate gonadotrophin releasing hormone (↓ LH/FSH) – 2° hypogonadism
Isolated ACTH / TSH / GH possible too
Treatment of Hypopituitarism
Secondary… Cause Treatment
can’t rely on TSH like in 1° (TSH messed up!)
Hypothyroidism ↓ TSH
need to rely only on free T4 & symptoms
Testosterone (patch, gel, injections)
Sex hormone deficiency ↓ GRH
estrogen / progesterone (OCP)
Prednisone / dexamethasone (potencies different; all replace glucocorticoids)
Maintenance dose + extra dose for stress
Glucocorticoid deficiency ↓ ACTH o Extra maintenance if just a little sick
o 10x dose if severe illness, surgery, etc
o Wear medical alert tag
Vasopressin:
brings in free water back from renal tubules into plasma
Binds V2 receptors translocates aquaporins via cAMP into
apical membrane
Plasma osmolarity is #1 regulator of [vasopressin] in the blood
31
Pathophysiology:
Can’t get aquaporins in to concentrate urine very dilute urine, polyuria
dehydration / hypotension if can’t get to water!
Etiology:
• Post-operative (e.g. transsphenoidal) – most common • Metastatic tumor
• Head trauma (#2) • Infiltrative disorder (e.g. sarcoid)
• Idiopathic (#3) • Aneurysm
• CNS tumor (e.g. craniopharyngioma) • Pituitary adenoma
Dx of DI
Serum osmolarity > 295 (hyperosmolar)
Urine osmolarity < 800 – should have tons of vasopressin; should be around 1200! Not diluting!
Water deprivation test: deprive pt of fluids, then get these values (keep from compensating by drinking)
32
Endocrinology of Aging
Thyroid Hormone
Overt or subclinical hypothyroidism affect 7-15% of people > age 60 (esp women)
Overt hypothyroidism hyperlipidemia, ↑ risk CHD. MUST TREAT
Subclinical hypothyroidism: common; TSH ↑ but no symptoms
o ↑ risk of overt hypothyroidism
o So: check TSH levels, follow ± treat (?) subclinical hypothyroidism in the elderly
Consequences of Aging
From graphs:
↓ muscle strength
Body composition:
↓ muscle
↑ fat
Growth Hormone
Note lower levels, smaller peaks with age
↓ somatostatin C (like IGF-1) with age, too (gradual)
33
GH replacement in healthy elderly
Effects of GH deficiency
Effects Potential Risks
↓ muscle mass Joint pain
↑ lean body mass (good)
↑ intra-abdominal fat Carpal tunnel
↓ total body, abdominal fat
↓ bone mass Fluid retention
↑ fracture risk HTN
NO CHANGE in FUNCTIONAL STATUS
↑ SBP Diabetes
Total / HDL chol = inconsistent
Hyperlipidemia Cancers? Accelerated aging?
DHEA (dehydroepiandrosterone)
DHEA and DHEAS (DHEA sulfate) are readily interchangeable
Synthesized in zona reticularis of the adrenal gland
Secretion mediated by ACTH but no feedback on pituitary/adrenal axis (no way to ↓ ACTH)
In aging: marked ↓ DHEA levels with time (both men & women)
Variable amount of decline from one to another
DHEA often marked as a super-pill to prevent all sorts of aging stuff
o No evidence whatsoever to support these claims (not a fountain of youth, miracle pill, antidote for aging)
Major effect of taking DHEA (even by mouth): raises DHEA / DHEAS blood levels
At least you can take it by mouth!
A little ability to increase estrogen / T levels? Maybe IGF-1? LDL cholesterol lowering? Not well proven.
Maybe ↓ body fat, ↑ body mass. Probably does “increase skin status”
RCT in elderly:
NO physiologically relevant beneficial effects on body composition, physical performance, insulin sensitivity, QOL
Only should be used for adrenal insufficiency (not for healthy old folks)
Testosterone
↑ age slow ↓ testosterone, ↓ male sexual function: But no evidence that those two things are related or causal
Risks of testosterone replacement: ↑ BPH, worse prostate cancer, sleep apnea, ↑ Hct, ↓ HDL-chol, Sleep apnea
Take-home: don’t give T unless the patient is severely T deficient (from another cause)
34
Adrenal Pathophysiology & Multiple Endocrine Neoplasia
Overview of Adrenal Pathophysiology
Glucocorticoid & mineralocorticoid deficiency Addison’s disease, Congenital Adrenal Hyperplasia
Glutocorticoid excess Cushing’s syndrome
Mineralocorticoid excess Hyperaldosteronism
Catecholamine excess Pheochromocytoma
Multiple Endocrine Neoplasia syndromes
Normal Embryology, Anatomy, & Physiology
Embryology
Adrenal cortex / medulla are functionally separate organs
Cortex: mesynchemal origin; invaded by neural crest cells (2 mo gestation)
Medulla: NCC chromaffin cells (secrete catecholamines) under ↑ local *glucocorticoid+
Anatomy
Note that :
Cortex / medulla have separate arterial supplies
Medulla exposed to cortical venous effluent
Nerve supply:
Cortex: efferent symps / parasymps regulate blood flow
Medulla: symps catecholamine release
Corticosteroids:
glucocorticoids (e.g. cortisol)
mineralocorticoids (e.g. aldosterone)
Cardiovascular Actions
Goal: maintain blood pressure
Cortisol (glucocorticoid) Aldosterone (mineralocorticoid)
Generally works faster Generally works on longer time scale
↑ myocardial contractility, ↑ SV, CO ↑ renal Na retention, K excretion
↑ vascular sensitivity to pressor effects of ↑ intravascular volume
catecholamines Some direct effects on myocardium too
Chronic ↑ glucocorticoids / aldosterone hypertension
35
CHO / Lipid metabolism
Goal: maintain fuel to brain (↑ blood glucose)
Immune function
Goal: limit inflammatory response to infection – a “check” to keep immune system from getting out of control
Chronic glucocorticoid excess excess immune suppression ↑ susceptibility to infection (bacterial / viral / fungal)
CRH pulses:
Stimulate ACTH synthesis & secretion
o Important for daily-type stresses, diurnal variation, etc.
In extreme stress: vasopressin can also cause ACTH release
ACTH pulses:
Stimulate secretion of:
o cortisol (principal glucocorticoid)
o aldosterone (mineralocorticoid)
o DHEAS / androstenedione (weak androgens)
↑ steroid hormone biosynthesis (↑cholesterol pregenolone conversion – rate limiting step, + other steps)
↑ adrenal growth
36
Clinical significance
Resistance to negative feedback is the hallmark of glucocorticoid excess (Cushing’s Syndrome)
Withdrawing exogenous glucocorticoids (e.g. post therapy) may suppress HPA axis
o Already ↓ CRH, ACTH from ↑ exogenous glucocorticoids
Mineralocorticoids: Regulation
Produced in zona glomerulosa (e.g. aldosterone: “salt”)
Clinical significance:
ACTH deficiency doesn’t usually produce mineralocorticoid deficiency, but
ACTH excess can lead to mineralocorticoid excess
37
Adrenocortical Insufficiency
Primary AI: indicates damage to adrenal cortex (Addison’s disease) Primary Secondary
Adrenals knocked out so ↓ aldo, ↓ cortisol ACTH High Low
↑ CRH, ACTH (negative feedback from cortisol removed) Cortisol Low Low
↑ renin, ↑ AT I/II (↓ aldosterone ↓ renal blood flow) Aldosterone Low Normal
Severity depends on
Rate, degree of loss of adrenal function
Whether aldosterone secretion is preserved
Level of concurrent physiological stress
Symptoms Signs
Weakness Abdominal pain Weight loss Dehydration*
Sleepiness / fatigue Postural light-headedness* Hyperpigmentation* Loss of pubic / axillary hair
Anorexia Salt craving Hypotension*
Nausea / vomiting
* especially in primary adrenal insufficiency
Addison’s Disease = autoimmune 1° adrenal insufficiency
Lab findings
HypoNa* ↑ BUN/Creatinine* Eosinophilia
HyperKa* HyperCa (rare) Lymphocytosis
Hypoglycemia Anemia
*mostly primary (vs secondary)
Short ACTH (cortrosyn) stimulation test: Best initial study of choice for adrenal insufficiency of any cause
Give ACTH, check cortisol (adrenals should produce cortisol > 18 mcg/dL)
But won’t work in recent onset 2° AI (adrenals haven’t atrophied yet)
39
Congenital Adrenal Hyperplasia
Family of disorders with specific defects in steroid biosynthetic enzymes
Relative ↓ in cortical secretion ↓ feedback suppression of CRH, ACTH
↑↑ ACTH secretion ↑ production of cortisol precursors (upstream of enzymatic block ↑ androgens)
Long term ↑↑ ACTH overgrowth of adrenal glands (hyperplasia)
40
Etiologies of Hypercortisolism
Cushing’s disease: pituitary ACTH-secreting tumor
Ectopic:
ACTH-dependent
o small cell lung cancer
o Carcinoid, medullary thyroid, pheochromocytoma
Exogenous glucocorticoid treatment (#1 – iatrogenic)
ACTH-independent
Adrenal adenoma or carcinoma
Mostly in severe alcoholics (can resolve if stop EtOH)
Pseudo-Cushing’s
Also possible in major depression can get central activation of axis
Diagnosis of hypercortisolism
INITIAL STUDIES
Urinary free cortisol
24 h urine collection measure cortisol
Method:
(24h: integrates circadian variation)
Cushing’s syndrome: ↑↑ (3x nL)
Results: Milder elevations: Cushing’s, pseudo-Cushing’s, or
stress (repeat test)
Comments: INITIAL STUDY OF CHOICE
CONFIRMING HYPERCORTISOLISM
LOW-DOSE dexamethasone suppression test
Give dexamethasone 0.5mg po q6h x 2d
Method:
Collect plasma cortisol
Normal: should suppress plasma cortisol (< 1.8mcg/dL)
Results:
Cushing’s: have impaired feedback suppression by low doses of exogenous corticosteroid (> 1.8 mcg/dL)
Comments: Doesn’t distinguish Cushing’s disease vs other causes of hypercortisolism
41
BIOCHEMICAL LOCALIZATION
Plasma ACTH
Method: Collect ACTH from plasma
42
Treatment of hypercortisolism
Etiology Treatment options
Trans-sphenoidal pituitary surgery
Cushing’s disease
Post-operative pituitary irradiation
Adrenal tumors Adrenal surgery
Ectopic ACTH Surgery (if possible)
Cortisol synthesis inhibitors (ketoconazole, metyrapone, mitotane)
Refractory / inoperable disease
Rarely: bilateral adrenalectomy
Hyperaldosteronism
Endocrine causes of hypertension: Cushing’s syndrome, Hyperaldosteronism, or pheochromocytoma
Clinical features:
hypoK: urinary potassium wasting
hyperNa: suppressed plasma renin (in 1° hyperaldosteronism)
Etiologies
due to adrenal cause (adenoma / hyperplasia), or idiopathic
Primary Diuretics, CHF, renal artery stenosis
Diagnostic evaluation
1. Identify primary vs. secondary hyeraldosteronism
a. After repletion of Na / K, check plasma renin / aldosterone
b. If ↓ renin and ↑ aldosterone, think primary
c. If ↑ renin and ↑ aldosterone, think secondary
2. Confirm non-suppressible hyperaldosteronism with salt-loading test (salt tabs or IV normal saline
3. If primary hyperaldosteronism, identify etiology (adrenal tumor vs. hyperplasia)
a. Adrenal CT
b. Adrenal vein sampling (aldosterone / cortisol)
c. Aldosterone-producing adenoma will lateralize; idiopathic hyperaldosteronism won’t
Treatment
Adenoma: surgery
Idiopathic: aldosterone receptor inhibitors (spironolactone . eplerenone)
43
Pheochromocytomas
Rare catecholamine-producing tumor of medulla
≈10% extra-adrenal (paragangliomas)
20% familial, 20% malignant
NEED TO DX (can provoke life-threatening hypertensive crisis)
The metabolites (metanephrines / VMA) are more stable (good for diagnostic measurement)
Clinical manifestations
More frequently paroxysmal than static (come in waves – minutes to hours)
Usually spontaneous; occasionally in response to abdominal manipulations / strenuous exertion
o not in response to emotional distress like anxiety
Can resemble hypoglycemia (activation of sympathetic pathways)
Symptoms / signs
Headache Nausea Chest pain Light-headedness
Diaphoresis Tremor Dyspnea HTN (often severe)
Palpitation Nervousness Pallor > flushing (vasoconstriction)
Locations of pheochromocytomas
Solitary adrenal Bilateral adrenal Extra-adrenal Malignant
80% 10% 10% 15-20%
Diagnosis
Recognize distinctive symptom complex or HTN that’s really severe
Then: confirm biochemically, then localize
44
Anatomic localization: with CT/MRI, 123I-MIBG, FDG-PET
Treatment
1. Pre-op preparation
a. Anesthesia, other major procedure w/o α-blocade could induce hypertensive crisis
b. α-adrenergic blockade (phenoxybenzamine usually used)
c. AVOID ISOLATED β-BLOCKER USE (can worsen HTN by inhibiting β-2 adrenergic receptors)
2. Adrenalectomy (laparoscopic)
Diagnosis:
Ionized calcium, PTH, FHx Gene testing difficult Prolactin, gastrin, others
Treatment
Parathyroid: 4 gland resection with forearm re-implantation
Pituitary: similar indications for surgery / DA agonists as in sporadic disease
GI:
o PPI for gastrinoma
o others have similar indications for surgery,
o somatostatin analogues to control hypersecretion in inoperable tumors
3 characteristic syndromes
MEN 2A MTC (>90% by age 30), pheo (≈50%), hyperparathyroidism (≈15%)
MEN 2B MTC (early onset, often aggressive), frequent pheo, mucosal ganglioneuromas, marfanoid
FMTC Isolated MTC, often later onset / less penetrant
Diagnosis:
Need DNA testing (RET gene mutation) – test known MEN2 families & MTC pts, even w/o obvious FHx
If test positive in asymptomatic person (e.g. relative) prophylactic childhood thyroidectomy (prevent MTC)
Surveillance for pheochromocytoma & hyperparathyroidism
45
Gender Development
Introduction
Original theories of gender development: learning influenced psychosexual development
Current model: androgen exposure, genes on Y chromosome
Novel predictors: parent attitudes may play a role
Importance of studying: influences how we understand sex and gender
Definitions
Gender Identity (GI): f undamental sense of belonging to one sex
Gender role (GR): behavior designated as masculine or feminine
Sexual orientation: attraction to sexual partners
DSD: disorders of sexual development
o (sensitive to patients: replace intersex, pseudohermaphrodites, sex reversal, etc)
Embryology
Sex ducts: all embryos start out with ‘em; may or may not continue
Male development
If embryo is 46XY and SRY+, develops into testis; makes:
Makes Mullerian ducts disappear
Mullerian inhibiting factor (MIF) peptide hormone
(embryo won’t have female internal reproductive structures)
Promotes Wolffian duct development
Testosterone androgen
(embryo will have male internal reproductive structures)
DHT (dihydrotestosterone) Promotes masculinization of external genital structures
more potent androgen
(5-α reductase: T DHT) (embryo will have male bits)
46
Optimal Gender Theory (John Money)
John Money (Hopkins PhD – gender identity clinic)
Identified gender identity vs gender role
Believed that GI is learned, GR is in part hormonally programmed
Simple virilizers (≈ prader 0-2) or salt-losers (prader 3-5 – tend to lose salt)
47
Raised female (external) but have had lots of androgen exposure
Should have both Mullerian & Wolffian ducts (no MIF but yes T)
Totally functional as females, but with Wolffian ducts too
o Can’t ethically take away child’s fertility potential to raise as a boy
Research question: If prenatal androgen exposure is important, should have more masculinization with ↑ androgens
Salt-losers have more androgen exposure than simple virilizers; compare to sisters / controls
Question Result
Satisfaction with female rearing (better off as male?) No differences between groups (GENDER IDENTITY)
Dose-response with androgen exposure
Have you questioned your female rearing?
(I’m hirstute, I have menstrual problems, etc.)
Sexual orientation (Kinsey scale) Salt users more towards bisexual end of scale
Vs. friends, etc.: how masculine are you? Dose-response with ↑ masculinity (GENDER ROLE)
Everybody says they ↑ femininity with time
Past life: How feminine? How masculine? (Learning? Puberty? Combo?)
Salt-losers: ↑ masculinity early, but ↓ with time
Question: does rodent model apply to humans? Exposed to lots of T in utero (should masculinize brain?)
All CAIS females were heterosexual, satisfied with gender identity role
Really feminine! Maybe because the T is being converted to E(not best population to study)
48
Study: various conditions; all 46,XY DSD with ≈ the same external genital appearance
Reared female Reared male
Gender identity 75% satisfied 75% satisfied
(satisfaction with rearing) 25% dissatisfied 25% dissatisfied
(“intersex”, homosexual orientation) (intersex, gender change)
Sexual orientation 39% exclusively female heterosexual 95% exclusively male heterosexual
Gender role More feminine (↑ with time) More masculine (↑ with time)
Early androgen exposure might have role in sexual orientation – or maybe other factors at play?
“Genes encoded on the Y chromosome masculinize the brain and behavior in humans”
Not true for GI, GR, or sexual orientation (CAIS and CGD)
“Both early androgens / Y-chromosome masculinize brain / behavior in an additive / synergistic way)
Not true for GI (46,XY with ambiguous genitalia reared female)
May be true for GR (46,XY with ambiguous genitalia reared female)
Not true for sexual orientation (only 39% of 46,XY with ambiguous genitalia reared female are heterosexual)
Parental factors?
Parental support purported to be primary factor that promotes well-being (not studied much)
Hypothesis:
Maybe parents of children with life-threatening DSD at greatest risk for stress, overprotection, perceived child vulnerability
Maybe parents reading children discordant with genetic sex at greatest risk for stress, overprotection, etc.
Maybe parents of children with ambiguous genitalia at greatest risk for stress/overprotection / perceived child vulnerability
Turns out that ambiguous genitalia and raising girls will ↑ parental stress
49
Puberty
Puberty: physiological process causing development of 2° sexual characteristics and leading to reproductive maturity.
Normal Puberty: Physiology
50
Theca cells
LH hits GCPR AC ↑ cAMP ↑ androgen synthesis Leydig cells
↑ androstendione steroid crosses to follicular cells LH hits GCPR ↑ AC ↑ cAMP
↑ production of testosterone
Follicular cells
FSH hits GCPR ↑ AC ↑ cAMP → ↑ conversion of (FSH acts on Sertoli cells to promote somatogenesis)
o Testosterone to estradiol (aromatase) Not involved in steroid production
o Androstenedione (from theca cells) to estrone
Infancy
Pulsatile secretion of GnRH at delivery!
T production in males (peaks at 3 mo)
GnRH Secretion of LH / FSH
E2 production in females (peaks at 6 mo)
3-8 yrs
GnRH not released (so serum LH, FSH, T, E2 low – axis quiescent)
6-7yrs: start secreting adrenal androgens (DHEA / DHEAS)
51
11-14 yo: Male puberty begins
Pulsatile secretion of GnRH pulsatile secretion of LH / FSH
LH to Leydig cells testicular enlargement, T production (some E2 too)
o T ↑ penile length, male pattern hair
o T + E2 skeletal growth, close growth plates
FSH to Sertoli cells spermatogenesis
Boys vs Girls
Why are men taller than women?
Peak height velocity is earlier & lower in girls than boys
Growth spurt lasts longer in males
52
Definitions
Females Males
Breast development < 8 yrs and/or Testicular enlargement < 9 yrs and/or
Precicious puberty*
Pubic hair development < 8 yrs Pubic hair development < 9 yrs
Secondary characteristics ≥ 13yrs
Delayed puberty Testicular enlargement ≥ 14 yrs
Menarche ≥ 16yrs
Proposed (controversial): breast development <7 in whites, <6 in AA unless rapid progression
Precocious Puberty
Basic approach:
Isosexual Contrasexual (always peripheral origin)
Central: premature activation of hypothalamus / pituitary
↑ all gonadotropin levels (LH/FSH/T/E2) Males breast development
Diagnostic Criteria
Tanner 2 breast < 8 or enlarged testes < 9
Accelerated growth velocity
Accelerated bone age (degree of maturation of bones of left hand - ↑ with sex steroids)
Pubertal LH/FSH or pubertal response of LH/FSH to GnRH stimulation
Exclude pathologic etiologies of CPP before you call it idiopathic (imaging)
Effects:
o ↓ growth velocity (↓ sex steroids), ↓ bone age advancement
o Final height improved (may not reach target height
o Fertility maintained
53
Isosexual gonadotrophin-independent (peripheral) precocious puberty
2° sex characteristics appropriate for sex; ↑ T/E2 but ↓LH/FSH (neg feedback)
54
Contrasexual gonadotrophin-independent (peripheral) precocious puberty
2° characteristics not appropriate for one’s sex
Delayed Puberty
Females Males
Secondary characteristics ≥ 13yrs
Testicular enlargement ≥ 14 yrs
Menarche ≥ 16yrs
Classification
Hypergonadotropic hypogonadism Hypogonadotropic Hypogonadism
↑ LH/FSH but gonads not working ↓ LH/FSH (pituitary or hypothalamic dysfunction) gonadal failure
aka primary hypogonadism, gonadal failure Secondary hypogonadism
55
Growth
Any serious illness can affect a child’s growth: an important “vital sign” in pediatrics
o normal growth in a kid doesn’t r/o serious illness, but abnormal growth ↑ concern for significant illness
Normal growth
Height / length most affected by hormones
Growth curves: the importance is in both:
o the absolute value (e.g. way over / under normal)
o the trajectory (e.g. from 75th to 10th %ile rapidly)
Normal growth:
• Height between the 3rd and 97th percentiles
• Track along a percentile line on the growth curves: mostly true from 2 to 8-10 yo
• Growth velocity > 2 inches/yr (5 cm/yr): mostly true after 4 yo
• Height appropriate for genetic potential
Normal growth may not follow all of the characteristics of normal growth: atypical isn’t always abnormal
But evaluate these kids (e.g. look at growth & compare to normal growth variants)
56
Not growing ≥ 2 in/yr (5 cm/yr) after 4yo
Note that 50% of all boys will have ≤ 5cm/yr growth in early adolescence
th
Nadir of 50 %ile hits the cutoff
Sensitivity / specificity of 5cm/yr changes with age! Not very specific in early adolescence.
Note too that later puberty means your growth velocity nadir occurs later & lower
> 50% of these kids will have growth ≤ 5cm / yr
th
o Graph (lower) only 50 %ile lines
Interpret growth velocity in context of pubertal development
o Kids in middle of puberty should be growing faster
Delayed puberty (boys normally 9-14, girls normally 8-13; menarche ≈ 12.5)
o Delayed bone age
o Often have FHx of delayed puberty
o Growth velocity often dips below 5 cm/ yr
Etiology:
Normal variants of growth (genetic short stature, constitutional delay of growth & development)
Chronic systemic disease (may be only manifestation of dz, e.g. IBD)
IUGR (intrauterine growth retardation – 50% cases have poor catch-up growth)
Chromosomal abnormalities (Turner, Down)
Genetic syndromes (Prader Willi, Russel-Silver)
Skeletal abnormalities (chondrodysplasias, rickets)
HORMONAL ABNORMALITIES
Hormones involved
Stimulate growth Impair growth
Thyroid hormone
Glucocorticoids (cortisol) – slow linear
Growth hormone
growth & stimulate appetite (↑ weight gain)
Sex hormones (androgens, estrogens)
57
Hypothyroidism
Example: girl starts to cross %iles ↓, TSH is really high and T4 low: primary hypothyroidism.
o Treat with L-thyroxine; growth jumps back up
Etiology in peds:
Congenital Acquired
Autoimmune
Most from aplasia (1:3k, most sporadic) / dysplasia of thyroid
Primary (Hashimoto’s – mostly
Dyshormonogenesis too (aut-recessive, enzymes affected more rare)
adolescents)
Central Often with other pituitary hormone defects Worry about tumor, etc.
Evaluation: get TSH + Free T4 (1° & central hypothyroidism – need thyroxine for central)
Both are possible in kids!
Congenital hypothyroidism
Used to be leading cause of mental retardation; now have uniform newborn screening
If hypothyroidism is a possibility in children < 2-3 yrs old, test early (preserve brain development)
o Compare results to age-specific normal ranges!
Normal T4 range is higher than infants than adults (reported normal range often adult normal!)
IGF-1 levels are stable throughout the day (random samples are informative)
o Vs. growth hormone – random samples useless (varies throughout day)
58
Congenital Hypopituitarism
↓ GH especially for relevance of this talk
Suggestive findings:
Midline defects (cleft lip/palate, single central incisor)
Micropenis in male infant (< 2.0cm at birth) – from gonadotropin and/or GH deficiency
Hypoglycemia (from cortisol / GH deficiency)
Prolonged jaundice / hepatitis (hypothyroidism)
Visual problems
o Septo-optic-dysplasia: optic nerve atrophy, abnormality of corpus callosum, hypopituitarism
st
o Nystagmus in an infant may be 1 clue of visual impairment
Acquired hypopuitarism
↓ GH especially for relevance of this talk
Etiology:
Brain tumors, other malignancies , Histiocytosis X
Radiation Vascular disturbances (strokes)
Trauma (MVA) Inflammatory disease (or autoimmune)
59
Growth Hormone Excess
Exceedingly rare
Marked by ↑ IGF-1 level
Results in
o abnormally tall adult stature (gigantism) if in kids
o Acromegaly if onset in adulthood
Boys Girls
Normal age of puberty onset 9-14 yo 8-13 yo*
First sign of central puberty Enlargement of testes (< 2.5 cm) Thelarche (breast development)
*Puberty beginning in girls between 6-8 yo may be normal!
Gonadal: generally present with androgen effect in boys and estrogen ≫ androgen effect in girls
o Tumor
o McCune – Albright Syndrome
o Testotoxicosis in boys (activating mutation of LH receptor
o Exogenous / environmental sources
Sample cases
60
Obesity
Definition of obesity: an accumulation of adipose tissue that is of sufficient magnitude to impair health
weight (kg)
Clinically: estimate using BMI BMI = BMI Classification
height in m 𝟐
< 18.5 Underweight
o Has limitations (Ray Lewis = 33 kg/m2) 18.5- 24.9 Normal
o Not good in muscular, ↑ fluid – weight needs to be fat! 25-29.9 Overweight
30-34.9 Class I Obesity
In children: usually use percentiles 35-39.9 Class II Obesity
th
o > 85 %ile for age / sex = at risk for overweight 40 Class III Obesity
th
o > 95 %ile for age / sex = overweight
Fat Distribution
Abdominal fat: visceral fat is really important clinically (vs. subcutaneous fat)
Measure by proxy:
Men Women
Waist Circumference > 40 in (102cm) > 35 in (88 cm)
Waist / Hip Ratio > 1.0 > 0.8
Epidemiology of Obesity
Hey, did you know there’s this series of maps that shows obesity trends over time in the US?
↑ obesity with:
Black > Hispanic > White; Bigger disparities in women, growing (ha!) in men
Living in states with a country radio station : NPR affiliate ratio of > 5:1 (especially Mississippi)
61
Pathophysiology of Obesity: Energy Balance
Calories in = calories out.
If intake > expenditure, you gain weight. Details unknown.
Genetics, social / cultural issues, psychological issues, cytokines / hormones (leptin,
adiponectin, etc) probably involved.
Regulation
Hypothalamus involved a lot (CNS side)
o regulates satiety / appetite
Fat cells produce Leptin, Ghrelin, etc.
GI system produces CCK, ghrelin, etc.
Polygenic Obesity
Probably explains “susceptibility” to obesity; may have multiple variants
o Previous evolutionary advantage? “thrifty” metabolically?
Consider endocrine syndrome if growth velocity decreases (r/o hypothyroidism, GH deficiency – think Cushing’s?)
GI: incontinence, impotence, kidney stones, NASH Cardiovascular: cerebrovascular disease, CAD, cor
Repro: ↓ fertility, polycystic ovary syndrome, impotence pulmonale, HTN
Derm: chronic skin infections, acanthosis nigrans Oncology: ↑↑ cancer
Vascular: venous insufficiency, DVT Pulm: Asthma, sleep apnea, Pickwickian syndromes
Many, many more…
End result: ↑ mortality, years of life lost (BMI 45 @ age 20: lose ≈ 11 yrs of life!)
J-shaped curve: ↑ with underweight & overweight; Asians ↑ morbidity with lower BMI (different genes!)
63
Other consequences of obesity
Discrimination (housing, employment, socially) Disability
↓ QOL $$$ ($78.5B in 1998, ≈9% total expenditure)
Why is obesity so bad?
Fat isn’t just an inert storage tissue: adipose tissue is an endocrine organ
o Adipokines (Leptin, IL-6, TNF-α, adiponectin, etc) have many effects
o ↑ monocytes, lymphocytes – inflammatory state
o + feedback loops set up downward spiral
Treatment of Obesity
Lifestyle, medical, or surgical
Lifestyle modification
Combo of low calorie diet, ↑ physical activity, behavior modification
Realistic goals: aim for “healthier weight,” NOT ideal weight
o Slow, incremental process to goal
o Short-term goal: 5 TO 10 % LOSS, 1 TO 2 LBS / WK
o Interim goal: maintenance
o Long-term goal: additional wt loss, if desired, + long-term maintenance
Lifestyle: Diet
Diet: look for 500-1000 kcal deficit / day,
Women: 1000-1200 kcal/day Balanced deficit diet
Men, women > 165 lbs: 1200-1600 kcal/day CHO (55%) high fiber (↑ satiety)
try to lose 1-2 lbs / wk 3500 kcal = 1 lb Protein (15%) lean sources
Total fat (< 30%) “Low fat” useful – if ↓cal too!
Low-carb diets (15-20 carbs / piece of bread)
Atkin’s diet: induction phase (20g/day carbs) gradual ↑ carbs
South beach: low carb, but more allowance for fruits / veggies
Protein power: 75 gm protein / kg IBW, < 30g carbs
Carbohydrate addict’s diet: 2 complementary meals + 1 reward meal
Low fat diets: e.g. Ornish, < 10% cal from fat
Meal replacements: e.g. SlimFast, may be better than traditional diets
Want 30-60 min of moderate intensity physical activity on most / all days of week!
You need to exercise a lot to burn significant amounts of calories (obese = need less exercise to burn same amt)
Exercise alone - not really good for weight loss
64
Lifestyle: behavior modification
Self monitoring is most effective tool (write down what you eat & when you exercise)
Stimulus control, meal planning, contingency management can be used too
± Cognitive restructuring, problem-solving stress-management training
Pharmacotherapy of Obesity
Two FDA-approved drugs for long-term (2yr) use; to be used with comprehensive program
BMI ≥ 30 or BMI ≥ 27 with risk factors / diseases (HTN, dyslipidemia, CVD, type 2 DM, sleep apnea)
Other drugs: FDA approved for other indications (but if you can kill 2 birds with one stone…)
Fluoxetine, sertraline (Prozac, Zoloft) Metformin (Glucophage)
Buproprion (Wellbutrin) Byetta
Topirimate (Topamax)
Investigational drugs
Leptin 3 -adrenergic receptors
Ciliary neurotrophic factor (rhvCNTF) Cholecystokinin-A receptors
Cannabinoid-1 receptor blocker (rimonabant) – was promising but FDA didn’t approve (psych side effects)
Supplement: billions of dollars / yr, but generally unsafe: either toxic or actual drug used in unregulated way
65
Bariatric Surgery
Indicated for patients with class III obesity
BMI ≥ 40 kg/m2 or
BMI ≥ 35 with comorbid conditions AND failure of prior therapy
o Most insurers require period of “medically supervised” wt loss before approving surgery
Contraindicated if…
• Reversible condition causing the obesity • Lack of comprehension of (or ability to comprehend)
• Current drug or alcohol abuse risks, benefits, outcomes, alternatives and/or lifestyle
• Uncontrolled, severe psychiatric illness changes required with surgery
Mechanism of changes:
↓ calorie absorption (↓ intake + malabsorption, improvements from wt loss)
Neuroendocrine – GI axis involved? May see improvements in glucose homeostasis before wt loss in RYGB
Prevention of Obesity
66